SCHEMBL13245197

SCHEMBL13245197

O=C(O)c1ccc(C#CC#CC2CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.46
RARB P10826 3/20 0.45
RARG P13631 3/20 0.45
PTPN11 Q06124 1/20 0.42
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
FFAR4 Q5NUL3 2/20 0.41
CYP26A1 O43174 1/20 0.41
CYP3A4 P08684 1/20 0.41
RARA P10276 1/20 0.41
CRABP2 P29373 1/20 0.41
HAO1 Q9UJM8 1/20 0.40
MMP13 P45452 1/20 0.39
GRM5 P41594 2/20 0.38
SRD5A2 P31213 2/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
TYR P14679 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022123 0.98 FFAR1 (0.45) FFAR1RARBRARGPTPN11TP53
SCHEMBL3019877 0.93 FFAR1 (0.46) FFAR1RARBRARGPTPN11TP53
SCHEMBL18712239 0.92 GRM5 (0.45) FFAR1RARBRARGPTPN11TP53
SCHEMBL13737676 0.90 FFAR1 (0.43) FFAR1RARBRARGPTPN11TP53
SCHEMBL3008201 0.89 HAO1 (0.46) FFAR1RARBRARGPTPN11TP53
SCHEMBL927052 0.87 FFAR1 (0.58) FFAR1RARBRARGPTPN11TP53
SCHEMBL13740624 0.84 FFAR1 (0.38) FFAR1RARBRARGPTPN11FFAR4
SCHEMBL2679567 0.83 TSHR (0.60) RARBRARGPTPN11TP53TSHR
SCHEMBL14724508 0.82 FFAR1 (0.40) FFAR1FFAR4HAO1GRM5
SCHEMBL13738104 0.82 RARB (0.39) FFAR1RARBRARGPTPN11TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171400-A1 AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS X-BIOTIX THERAPEUTICS, INC. 2025-05-29 US disclosed
US-12227475-B2 Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions X-BIOTIX THERAPEUTICS, INC. 2025-02-18 US disclosed
US-20240425447-A1 BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME UNIV DUKE (US) 2024-12-26 US disclosed
US-12103904-B2 Benzoylglycine derivatives and methods of making and using same DUKE UNIVERSITY (US) 2024-10-01 US disclosed
EP-4286001-A2 BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME Duke University (US) 2023-12-06 EP disclosed
EP-3448375-B1 BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME UNIV DUKE (US) 2023-09-27 EP disclosed
US-20230139502-A1 AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS X-BIOTIX THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20210206715-A1 Benzoylglycine Derivatives and Methods of Making and Using Same DUKE UNIVERSITY (US) 2021-07-08 US disclosed
US-20210206715-A1 Benzoylglycine Derivatives and Methods of Making and Using Same DUKE UNIVERSITY (US) 2021-07-08 US disclosed
US-11034649-B2 Benzoylglycine derivatives and methods of making and using same DUKE UNIVERSITY (US) 2021-06-15 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
EP-2662353-A2 Antibacterial agents Achaogen, Inc. (US) 2013-11-13 EP disclosed
EP-2662353-A2 Antibacterial agents Achaogen, Inc. (US) 2013-11-13 EP disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed
US-20100190766-A1 ANTIBACTERIAL AGENTS ACHAOGEN, INC. (US) 2010-07-29 US disclosed
WO-2008154642-A2 ANTIBACTERIAL AGENTS ACHAOGEN, INC. (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206715-A1 Benzoylglycine Derivatives and Methods of Making and Using Same B3GAT3, GLO1, GLMN FFAR1 1545/4885RARB 3367/4885RARG 1927/4885
US-20230139502-A1 AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS AADAC, AZI2, CBX7 FFAR1 2469/4885RARB 2108/4885RARG 2123/4885
US-11034649-B2 Benzoylglycine derivatives and methods of making and using same B3GAT3, GLO1, GLMN FFAR1 1545/4885RARB 3367/4885RARG 1927/4885
US-20100190766-A1 ANTIBACTERIAL AGENTS MRPL21, SI, ABCB11 FFAR1 1753/4885RARB 1644/4885RARG 2102/4885
US-12227475-B2 Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions AADAC, AZI2, CBX7 FFAR1 2469/4885RARB 2108/4885RARG 2123/4885
US-20240425447-A1 BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME BPGM, B3GAT3, GLMN FFAR1 2268/4885RARB 3899/4885RARG 2717/4885
US-20250171400-A1 AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS AADAC, AZI2, CBX7 FFAR1 2469/4885RARB 2108/4885RARG 2123/4885
US-12103904-B2 Benzoylglycine derivatives and methods of making and using same B3GAT3, GLO1, GLMN FFAR1 1545/4885RARB 3367/4885RARG 1927/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 FFAR1 1061/4885RARB 2653/4885RARG 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.